Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 4/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CTRC | Q99895 | 2/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.46 |
| ▸ | CDH1 | P12830 | 1/20 | 0.45 |
| ▸ | APC | P25054 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2701888 | 0.87 | MAP4K4 (0.52) | MAP4K4HCAR2NAPRT | |
| SCHEMBL2127952 | 0.84 | KMO (0.54) | TSHRSRD5A2NAPRTKMO | |
| SCHEMBL2490941 | 0.81 | SLC6A4 (0.50) | MAPTCNR1 | |
| SCHEMBL30791383 | 0.80 | CTSA (0.56) | MAP4K4AURKATPX2CNR1 | |
| SCHEMBL16554974 | 0.80 | CTSA (0.56) | MAP4K4AURKATPX2CNR1 | |
| SCHEMBL411087 | 0.79 | CNR1 (0.51) | MAP4K4AURKATPX2CNR1 | |
| SCHEMBL5355700 | 0.79 | CNR1 (0.67) | MAP4K4SRD5A2CNR1 | |
| SCHEMBL27335823 | 0.77 | HPGDS (0.51) | MAP4K4AURKAEGLN1KMO | |
| SCHEMBL3536024 | 0.77 | ALOX15 (0.56) | MAP4K4ALOX15TSHRCTRCSRD5A2 | |
| SCHEMBL232290 | 0.76 | HCAR2 (0.50) | ALOX15TSHRSRD5A2HCAR2NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2613785-B1 | HETEROARYLMETHYL AMIDES | HOFFMANN LA ROCHE (CH) | 2015-07-29 | — | — | EP | disclosed |
| US-9090599-B2 | Heteroarylmethyl amides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8729105-B2 | Heteroarylmethyl amides | HOFFMANN LA-ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| EP-2613785-A1 | HETEROARYLMETHYL AMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| EP-2074096-B1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | HOFFMANN LA ROCHE (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-8188093-B2 | Pyrazinecarboxamide derivatives as HDL-cholesterol raising agents | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2450350-A1 | 3-Pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents | F. Hoffmann-La Roche AG (CH) | 2012-05-09 | — | — | EP | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
| US-7781593-B2 | CB1 cannabinoid receptor antagonists/inverse agonists; 5-(4-chloro-phenyl)-N-((1R,2R)-2-hydroxy-cyclohexyl)-6-(3-methoxy-propyl)-nicotinamide for example; eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), neuroinflammation, diarrhea, drug abuse | HOFFMANN-LA ROCHE INC. (US) | 2010-08-24 | — | — | US | disclosed |
| CN-101522626-A | 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents | HOFFMANN LA ROCHE (CH) | 2009-09-02 | — | — | CN | disclosed |
| CN-101516849-A | 5-phenyl-nicotinamide derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | CN | disclosed |
| EP-2074096-A1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| EP-2066636-A1 | 5-PHENYL-NICOTINAMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| US-20090143409-A1 | 3-PYRIDINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | ANDJELKOVIC MIRJANA | 2009-06-04 | — | — | US | disclosed |
| US-20080085906-A1 | 3-Pyridinecarboxamide derivatives as HDL-cholesterol raising agents | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-10 | — | — | US | disclosed |
| WO-2008040651-A1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-10 | — | — | WO | disclosed |
| US-20080070931-A1 | CB1 cannabinoid receptor antagonists/inverse agonists; 5-(4-chloro-phenyl)-N-((1R,2R)-2-hydroxy-cyclohexyl)-6-(3-methoxy-propyl)-nicotinamide for example; eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), neuroinflammation, diarrhea, drug abuse | HOFFMANN-LA ROCHE INC. | 2008-03-20 | — | — | US | disclosed |
| WO-2008031734-A1 | 5-PHENYL-NICOTINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | MAP4K4 4374/4885AURKA 3488/4885TPX2 3747/4885 |
| US-20080085906-A1 | 3-Pyridinecarboxamide derivatives as HDL-cholesterol raising agents | CETP, APOB, LDLR | MAP4K4 3724/4885AURKA 4578/4885TPX2 1078/4885 |
| US-20080070931-A1 | CB1 cannabinoid receptor antagonists/inverse agonists; 5-(4-chloro-phenyl)-N-((1R,2R)-2-hydroxy-cyclohexyl)-6-(3-methoxy-propyl)-nicotinamide for example; eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), neuroinflammation, diarrhea, drug abuse | CNR2, CNR1, GPR119 | MAP4K4 2534/4885AURKA 4848/4885TPX2 4592/4885 |
| US-20090143409-A1 | 3-PYRIDINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | CETP, APOB, LDLR | MAP4K4 3724/4885AURKA 4578/4885TPX2 1078/4885 |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | MAP4K4 4374/4885AURKA 3488/4885TPX2 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.